09:52 AM EST - Resverlogix Corp. : Today announced the publication of a peer-reviewed article, entitled "Apabetalone, a Clinical-stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells" in the journal Biomedicines. Resverlogix Corp.
shares T.RVX are trading unchanged at $0.07.
